Summary by Moomoo AI
Moderna, a biotechnology company specializing in mRNA medicines, reported stable net product sales of $1.8 billion in Q3 2024, matching the previous year's quarter. The company saw a significant turnaround with earnings per share of $0.03, compared to a loss per share of $(9.53) in Q3 2023. Moderna's COVID-19 vaccine, Spikevax, and the newly approved RSV vaccine, mRESVIA, contributed to the sales. The company's diverse pipeline includes 36 development candidates across 45 programs, with 42 in clinical studies. Moderna's Canadian manufacturing facility in Quebec received a Drug Establishment License, with production expected to start in 2025. The company's RSV vaccine was approved by the FDA and the European Commission for adults aged 60 and older, and sales commenced in the U.S. in Q3 2024. Moderna also reported positive...Show More
